Crescent Grove Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.06M | Hold |
4,873
| – | – | 0.1% | 131 |
|
|
2025
Q4 | $1.11M | Sell |
4,873
-16
| -0.3% | -$3.65K | 0.1% | 123 |
|
|
2025
Q3 | $1.13M | Sell |
4,889
-581
| -11% | -$118K | 0.11% | 112 |
|
|
2025
Q2 | $1.02M | Sell |
5,470
-1,667
| -23% | -$310K | 0.1% | 114 |
|
|
2025
Q1 | $1.5M | Sell |
7,137
-553
| -7% | -$108K | 0.16% | 89 |
|
|
2024
Q4 | $1.37M | Buy |
7,690
+2,696
| +54% | +$496K | 0.14% | 100 |
|
|
2024
Q3 | $986K | Sell |
4,994
-544
| -10% | -$102K | 0.1% | 114 |
|
|
2024
Q2 | $950K | Sell |
5,538
-2,425
| -30% | -$402K | 0.1% | 114 |
|
|
2024
Q1 | $1.45M | Sell |
7,963
-200
| -2% | -$34.5K | 0.15% | 92 |
|
|
2023
Q4 | $1.27M | Sell |
8,163
-248
| -3% | -$36.2K | 0.14% | 99 |
|
|
2023
Q3 | $1.25M | Sell |
8,411
-2,951
| -26% | -$433K | 0.16% | 96 |
|
|
2023
Q2 | $1.53M | Buy |
11,362
+4,670
| +70% | +$685K | 0.16% | 80 |
|
|
2023
Q1 | $1.07M | Sell |
6,692
-3,893
| -37% | -$595K | 0.12% | 101 |
|
|
2022
Q4 | $1.71M | Buy |
10,585
+170
| +2% | +$26.1K | 0.18% | 79 |
|
|
2022
Q3 | $1.4M | Buy |
10,415
+6,639
| +176% | +$953K | 0.16% | 75 |
|
|
2022
Q2 | $578K | Sell |
3,776
-3,110
| -45% | -$475K | 0.06% | 152 |
|
|
2022
Q1 | $1.12M | Sell |
6,886
-74
| -1% | -$10.7K | 0.11% | 102 |
|
|
2021
Q4 | $942K | Sell |
6,960
-718
| -9% | -$84.8K | 0.09% | 122 |
|
|
2021
Q3 | $828K | Buy |
7,678
+3,854
| +101% | +$440K | 0.09% | 117 |
|
|
2021
Q2 | $431K | Sell |
3,824
-820
| -18% | -$92.4K | 0.05% | 161 |
|
|
2021
Q1 | $503K | Buy |
4,644
+1,341
| +41% | +$143K | 0.06% | 130 |
|
|
2020
Q4 | $354K | Buy |
3,303
+365
| +12% | +$35.1K | 0.05% | 137 |
|
|
2020
Q3 | $257K | Sell |
2,938
-5
| -0.2% | -$471 | 0.05% | 141 |
|
|
2020
Q2 | $289K | Hold |
2,943
| – | – | 0.06% | 118 |
|
|
2020
Q1 | $224K | Buy |
2,943
+78
| +3% | +$6.64K | 0.05% | 117 |
|
|
2019
Q4 | $254K | Sell |
2,865
-2,000
| -41% | -$166K | 0.04% | 137 |
|
|
2019
Q3 | $368K | Hold |
4,865
| – | – | 0.07% | 103 |
|
|
2019
Q2 | $354K | Sell |
4,865
-5,278
| -52% | -$415K | 0.07% | 105 |
|
|
2019
Q1 | $817K | Buy |
10,143
+3,100
| +44% | +$254K | 0.17% | 65 |
|
|
2018
Q4 | $649K | Sell |
7,043
-5,134
| -42% | -$451K | 0.14% | 85 |
|
|
2018
Q3 | $1.15M | Buy |
12,177
+220
| +2% | +$20.9K | 0.25% | 52 |
|
|
2018
Q2 | $1.11M | Sell |
11,957
-500
| -4% | -$48.8K | 0.27% | 52 |
|
|
2018
Q1 | $1.18M | Buy |
12,457
+500
| +4% | +$54.9K | 0.29% | 48 |
|
|
2017
Q4 | $1.16M | Hold |
11,957
| – | – | 0.29% | 47 |
|
|
2017
Q3 | $1.06M | Hold |
11,957
| – | – | 0.27% | 53 |
|
|
2017
Q2 | $867K | Buy |
+11,957
| New | +$804K | 0.25% | 53 |
|
Other funds holding ABBV
VCM
VPM
Crescent Grove Advisors's ABBV Position: Q1 2026 in Review
Crescent Grove Advisors held its AbbVie (ABBV) position steady in Q1 2026 at 4,873 shares worth $1.06M. The position accounts for 0.1% of the portfolio, ranked #131.
Crescent Grove Advisors first reported a position in ABBV in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.71M in Q4 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Crescent Grove Advisors held 4,873 shares of AbbVie worth $1.06M as of Q1 2026.
- Crescent Grove Advisors left its AbbVie share count unchanged in Q1 2026.
- AbbVie made up 0.1% of Crescent Grove Advisors's portfolio in Q1 2026, its #131 holding.
- Crescent Grove Advisors first reported a position in AbbVie in Q2 2017 and has held it in 36 quarters since.
- Crescent Grove Advisors's AbbVie position peaked at $1.71M in Q4 2022.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Crescent Grove Advisors's 13F filing for Q1 2026, filed 6 May 2026.